EZR and soft tissue sarcoma: In the present meta‐analysis, the results showed that ezrin overexpression was significantly correlated with poor survival and more advanced tumor progression in patients with bone and soft tissue sarcomas, which suggested that ezrin is a valuable prognostic biomarker as well as a potential therapeutic target, although further comprehensive investigations with consistent methodologies are needed to validate our results.